International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 184-188
OUR EXPERIENCE IN HODGKINS DISEASE
MEHMET DAĞLI
Ankara Onkoloji Eğitim ve Araştırma Hastanesi Hematoloji Kliniği, ANKARA
Keywords: hodgkin's disease, clinical features, survival, adult
Hodgkin's disease (HD) accounts for about 1% at newly diagnosed malignant disease and 40% of lymphoproliferative disease. In this study, 145 newly diagnosed Hodgkin's disease cases followed between 1993 to 2001 year in Ankara Oncology Hospital of Hematology Clinic were evaluated. There were 78 men (53.8%) and 67 women (46.2%) between 16 and 77 years old (mean:47). In accordance with the staging system of Ann-Arrbor patients were defined as follows: Stage I, 17 patients (11.7%); Stage II, 50 patients (34.5%); Stage III, 59 patients (40.7%); Stage IV, 19 patients (13.1%). Of the 145 patients 124 had B symptoms. According to Rye Classification; frequency of histologic subtypes showed 47.6% (69 patients) mixed cellularity, 27.6% (40 patients) nodular sclerosis 18% (20 patients) lymphocyte predominant, 6.8% (10 patient's) lymphocyte depletion type. Combination chemotherapy of ABVD was used as first line treatment in 117 patients (80.7%). MOPP chemotherapy was used as first line treatment at 28 patients (19.3%). Complete remission was achieved in 78.7% of patients (113 patients) and partial remission in 7.6% (11 patients) of patients. Response could not be obtained in 13.1% (21 patients) of patient's. Disease progression or recurrence was observed in 27.8% of patients in 84 months. Median recurrence was 13.6 months (3-23). Five year survival rate was found 71.4% of all patients, 86% in stage I - II, and 15% in stage III - IV (p=0.03).
MEHMET DAĞLI
Ankara Onkoloji Eğitim ve Araştırma Hastanesi Hematoloji Kliniği, ANKARA
Keywords: hodgkin's disease, clinical features, survival, adult
Hodgkin's disease (HD) accounts for about 1% at newly diagnosed malignant disease and 40% of lymphoproliferative disease. In this study, 145 newly diagnosed Hodgkin's disease cases followed between 1993 to 2001 year in Ankara Oncology Hospital of Hematology Clinic were evaluated. There were 78 men (53.8%) and 67 women (46.2%) between 16 and 77 years old (mean:47). In accordance with the staging system of Ann-Arrbor patients were defined as follows: Stage I, 17 patients (11.7%); Stage II, 50 patients (34.5%); Stage III, 59 patients (40.7%); Stage IV, 19 patients (13.1%). Of the 145 patients 124 had B symptoms. According to Rye Classification; frequency of histologic subtypes showed 47.6% (69 patients) mixed cellularity, 27.6% (40 patients) nodular sclerosis 18% (20 patients) lymphocyte predominant, 6.8% (10 patient's) lymphocyte depletion type. Combination chemotherapy of ABVD was used as first line treatment in 117 patients (80.7%). MOPP chemotherapy was used as first line treatment at 28 patients (19.3%). Complete remission was achieved in 78.7% of patients (113 patients) and partial remission in 7.6% (11 patients) of patients. Response could not be obtained in 13.1% (21 patients) of patient's. Disease progression or recurrence was observed in 27.8% of patients in 84 months. Median recurrence was 13.6 months (3-23). Five year survival rate was found 71.4% of all patients, 86% in stage I - II, and 15% in stage III - IV (p=0.03).